JUN and neoplasm: EGCG also targets urokinase plasminogen activator (u-PA), leading to a down-regulation of VEGF production in tumor cells and subsequent repression of AP-1, NF-kappaB and signal transducer and activator of transcription (STAT)-1 transcription factor pathway [140], [141].